top of page

Hello USA and Canada

Find the drug and healthcare news of the USA and Canada.

Eli Lilly Cuts Zepbound Prices on Single‑Dose Vials to Expand Obesity Drug Access in the US | iPharmaCenter

CMS Launches ACCESS Outcome-Aligned Payment Model for High-Burden Chronic Conditions | iPharmaCenter

FDA Approves KEYTRUDA and KEYTRUDA QLEX in Combination with Padcev as Perioperative Treatment for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer | iPharmaCenter

FDA Approves KEYTRUDA and KEYTRUDA QLEX in Combination with Padcev as Perioperative Treatment for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer | iPharmaCenter

FDA Approves KEYTRUDA and KEYTRUDA QLEX in Combination with Padcev as Perioperative Treatment for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer | iPharmaCenter

FDA Approves Epkinly in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma | iPharmaCenter

AstraZeneca's ADC Enhertu is now approved in US for HR-positive, HER2-low or ultra low breast cancer | iPharmaCenter

BeiGene's PD-L1 inhibitor Tevimbra approved in the US for advanced gastric or gastroesophageal junction (G/GEJ) cancers | iPharmaCenter

FDA Devices Approval | 2024 | Abbott News | iPharmaCenter

FDA Devices Approval | 2024 | Abbott News | iPharmaCenter

FDA Devices Approval | 2024 | Abbott News | iPharmaCenter

FDA Diagnostics Approvals | 2024 | FDA Approvals | iPharmaCenter

FDA Diagnostics Approvals | 2024 | FDA Approvals | iPharmaCenter

FDA Diagnostics Approvals | 2024 | FDA Approvals | iPharmaCenter

Centers for Disease Control and Prevention | CDC | iPharmaCenter | 2024

Centers for Disease Control and Prevention | CDC | iPharmaCenter | 2024

Centers for Disease Control and Prevention | CDC | iPharmaCenter | 2024

Express-Scripts | Pharmacy Benefit Manager | News | Updates | 2024 | US Healthcare | iPharmaCenter

Express-Scripts | Pharmacy Benefit Manager | News | Updates | 2024 | US Healthcare | iPharmaCenter

Express-Scripts | Pharmacy Benefit Manager | News | Updates | 2024 | US Healthcare | iPharmaCenter

Eisai's Leqembi received FDA approval for Alzheimer's | CMS coverage of Leqembi | ipharmacenter

Eisai's Leqembi received FDA approval for Alzheimer's | CMS coverage of Leqembi | ipharmacenter

Eisai's Leqembi received FDA approval for Alzheimer's | CMS coverage of Leqembi | ipharmacenter

COVID19 drug updates | FDA EMA approved COVID19 drugs

COVID19 drug updates | FDA EMA approved COVID19 drugs

COVID19 drug updates | FDA EMA approved COVID19 drugs

Genzyme's Xenpozyme approved for Acid Sphingomyelinase Deficiency | iPharmaCenter

Genzyme's Xenpozyme approved for Acid Sphingomyelinase Deficiency | iPharmaCenter

Genzyme's Xenpozyme approved for Acid Sphingomyelinase Deficiency | iPharmaCenter

Lilly's and Incyte's Olumiant approved for adults with severe alopecia areata

Lilly's and Incyte's Olumiant approved for adults with severe alopecia areata

Lilly's and Incyte's Olumiant approved for adults with severe alopecia areata

Myasthenia Gravis News | FDA and EMA approvals |

Myasthenia Gravis News | FDA and EMA approvals |

Myasthenia Gravis News | FDA and EMA approvals |

bottom of page